Literature DB >> 10205198

Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa.

J Wedemeyer1, A Lorentz, M Göke, P N Meier, P Flemming, C A Dahinden, M P Manns, S C Bischoff.   

Abstract

BACKGROUND: The beta chemokine monocyte chemotactic protein 3 (MCP-3) has chemoattractant and activating capabilities in monocytes, lymphocytes, eosinophils, and basophils. AIMS: To investigate MCP-3 expression in inflammatory conditions of the human intestinal mucosa. PATIENTS: Forty five colon biopsy specimens from 18 patients with inflammatory bowel disease (IBD; 16 specimens from inflamed and 10 from non-inflamed areas) and 19 control patients were examined.
METHODS: Immunohistochemical staining and reverse transcription polymerase chain reaction (RT-PCR) were used for MCP-3 detection in tissue sections. Intestinal epithelial cell lines (HT-29, Caco-2, T-84) were stimulated with interleukin (IL) 1beta, IL-6, and tumour necrosis factor alpha (TNF-alpha) and examined for MCP-3 protein and mRNA expression using immunocytochemistry and RT-PCR, respectively.
RESULTS: In tissue sections, MCP-3 protein was detected predominantly in epithelial cells, both in patients with IBD and in controls. MCP-3 staining was particularly pronounced at sites of active mucosal inflammation. The intensity of MCP-3 staining was positively correlated with the extent of epithelial destruction. In intestinal epithelial cell lines, MCP-3 mRNA was expressed, whereas MCP-3 protein was not consistently detected.
CONCLUSIONS: Our data show that MCP-3 protein is present in normal and inflamed intestinal tissue. MCP-3 production is substantially enhanced in areas of active inflammation, suggesting an immunoregulatory role of MCP-3 in intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205198      PMCID: PMC1727483          DOI: 10.1136/gut.44.5.629

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa.

Authors:  M C Grimm; S K Elsbury; P Pavli; W F Doe
Journal:  J Leukoc Biol       Date:  1996-06       Impact factor: 4.962

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo.

Authors:  R Gillitzer; U Ritter; U Spandau; M Goebeler; E B Bröcker
Journal:  J Invest Dermatol       Date:  1996-11       Impact factor: 8.551

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM)-1) expression and neutrophil adhesion.

Authors:  G T Huang; L Eckmann; T C Savidge; M F Kagnoff
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

6.  Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease.

Authors:  S C Bischoff; J Wedemeyer; A Herrmann; P N Meier; C Trautwein; Y Cetin; H Maschek; M Stolte; M Gebel; M P Manns
Journal:  Histopathology       Date:  1996-01       Impact factor: 5.087

Review 7.  Regulation and expression of chemokines: potential role in glomerulonephritis.

Authors:  Z Brown; R L Robson; J Westwick
Journal:  J Leukoc Biol       Date:  1996-01       Impact factor: 4.962

8.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Effect of c-kit ligand, stem cell factor, on mediator release by human intestinal mast cells isolated from patients with inflammatory bowel disease and controls.

Authors:  S C Bischoff; S Schwengberg; K Wordelmann; A Weimann; R Raab; M P Manns
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

View more
  15 in total

1.  Characterization of a spontaneously polarizing HT-29 cell line, HT-29/cl.f8.

Authors:  Deanne M Mitchell; Judith M Ball
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Nov-Dec       Impact factor: 2.416

2.  Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11.

Authors:  Amanda Waddell; Richard Ahrens; Kris Steinbrecher; Burke Donovan; Marc E Rothenberg; Ariel Munitz; Simon P Hogan
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

3.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.

Authors:  Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmada; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephan R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; Jean-Pierre Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwilliam; Mark Tremelling; Panos Deloukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly
Journal:  Nat Genet       Date:  2008-06-29       Impact factor: 38.330

Review 4.  Chemokines in the inflammatory bowel diseases.

Authors:  R P MacDermott
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

Review 5.  The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease.

Authors:  Jacque N Wilk; Janine Bilsborough; Joanne L Viney
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis.

Authors:  M Lampinen; M Carlson; P Sangfelt; Y Taha; M Thörn; L Lööf; Y Raab; P Venge
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

Review 7.  Role of chemokines and chemokine receptors in the gastrointestinal tract.

Authors:  Maureen N Ajuebor; Mark G Swain
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

8.  The atypical chemokine receptor D6 contributes to the development of experimental colitis.

Authors:  Yvonne Bordon; Chris A H Hansell; David P Sester; Mairi Clarke; Allan McI Mowat; Robert J B Nibbs
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

9.  CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue.

Authors:  Ulf Helwig; Paolo Gionchetti; Fernando Rizzello; Karen Lammers; Tanja Kühbacher; Stefan Schreiber; Marco Baggiolini; Mariagrazia Uguccioni; Massimo Campieri
Journal:  Int J Colorectal Dis       Date:  2003-06-25       Impact factor: 2.571

10.  CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease.

Authors:  S J Connor; N Paraskevopoulos; R Newman; N Cuan; T Hampartzoumian; A R Lloyd; M C Grimm
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.